Intercept Pharmaceuticals (ICPT) Stock: Flying On Financial Results

Intercept Pharmaceuticals ICPT Stock News

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) is flying early on in the trading session this morning, and for good reason. The company announced its financial results for the fourth quarter and full year, exciting investors and sending the stock for the top. Today, we’ll talk about: The financial results; what we’re seeing from ICPT stock as … Read more

Intercept Pharmaceuticals (ICPT) Stock: Running Up On Clinical Data

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) is having a great start to the trading session this morning, and for good reason. The company announced positive clinical data, exciting investors and pushing the stock on a run for the top. Today, we’ll talk about: The clinical data; what we’re seeing from ICPT stock as a result; and … Read more

Intercept Pharmaceuticals (ICPT) Stock: Surging On Label Change

Intercept Pharmaceuticals IncĀ (NASDAQ: ICPT) is having an overwhelmingly strong day in the market today, and for good reason. The company announced prescription information surrounding Ocaliva(R). Today, we’ll talk about the information that was released, what we’re seeing from ICPT as a result, and what we’ll be watching for with regard to the stock ahead. ICPT … Read more

Intercept Pharmaceuticals (ICPT) Stock: Gaining On Strong Earnings

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) is having an incredibly strong start in the pre-market hours this morning, and for good reason. The company reported its earnings for the third quarter, beating expectations and causing excitement among investors. Of course, our partners at Trade Ideas were the first to alert us to the gains. Today, we’ll … Read more

Intercept Pharmaceuticals (ICPT) Stock: Gaining Big On Rumors

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) Intercept Pharmaceuticals is having an incredibly strong day in today’s trading session. At the opening bell, the stock quickly found its way to the green. From there, we’ve seen steady gains. Then, minutes ago, the stock started screaming for the top. Below, we’ll talk about what we’re seeing in the … Read more

Intercept Pharmaceuticals (ICPT) Stock: FDA Approves Ocaliva

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) Intercept Pharmaceuticals investors have something big to be excited about. The company announced, late on Friday, that the FDA has granted the company approval on one of their liver treatments. Today, we’ll talk about the approval, what we’re seeing in the market as a result, and what we can expect … Read more

Intercept Pharmaceuticals (ICPT) Stock: Should You Be Worried About Declines?

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) Intercept Pharmaceuticals is having a rough day in the market today. However, after yesterday’s strong movement in the market, a big question is popping up for many. Should investors be concerned about the declines we’re seeing on ICPT today? Today, we’ll talk about why we saw strong gains on the … Read more

Intercept Pharmaceuticals (ICPT) Stock Climbs On Acquisition Rumors

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) Intercept Pharmaceuticals had an incredible day in the market on Friday, and for a very good reason. Rumors started to surface that the company is considering selling itself. Today, we’ll talk about the rumors, how the market reacted to the news, and what we can expect to see from ICPT … Read more

The Top 6 Best Analyst Coverage on Intercept Pharmaceutical Inc

By Cody Miecnikowski Intercept Pharmaceutical Inc (NASDAQ:ICPT), a clinical stage bio-pharmaceutical company focused on the development and commercialization of novel therapeutics to treat underserved liver diseases, is set to report second quarter 2015 earnings after market close on August 5. Wall Street analysts have been weighing in on ICPT throughout the year as the biopharmaceutical … Read more

Biopharmaceutical Summer Highlights: Intercept Pharmaceuticals, Receptos, and XOMA

By Sarah Roden Last week, Liana Moussatos of Wedbush released a report highlighting a list of upcoming catalysts for biopharmaceutical companies. Specifically, she noted forthcoming events for Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Receptos Inc (NASDAQ:RCPT), and XOMA Corp (NASDAQ:XOMA). Moussatos has a 51% success rate recommending stocks with a +32.6% average return per rating. Intercept Pharmaceuticals … Read more